Trial · NCT07884578
The Effectiveness of Extracorporeal Shock Wave Therapy for Elbow Osteochondritis Dissecans (OCD)
NCT07884578, Not applicable, Completed, Chang Gung Memorial Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effectiveness of Extracorporeal Shock Wave Therapy for Elbow Osteochondritis Dissecans (OCD). Trials, record NCT07884578. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884578
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effectiveness of Extracorporeal Shock Wave Therapy for Elbow Osteochondritis Dissecans (OCD)
- NCT number
- NCT07884578
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 9 participants, actual
- Lead sponsor
- Chang Gung Memorial Hospital
- Conditions
- Elbow Osteochondritis Dissecans
- Interventions
- Extracorporeal Shock Wave Therapy, Extracorporeal Shock Wave Therapy(no-energy)
- First posted
- 2026-10-20
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Visual Analogue Scale (VAS) | Baseline and 1、 3、 6、 12、 18 months. | The Visual Analogue Scale (VAS) is a tool commonly used to quantitatively assess the intensity of pain in patients. The two ends are labeled: • Left end (0 points): Represents "no pain at all". • Right end (10 points or 100 millimeters): Represents "the most intense pain imaginable". |
| Primary | Mayo Elbow Performance Score( MEPS) | Baseline and 1、 3、 6、 12、 18 months | The Mayo Elbow Performance Score (MEPS) is a professional assessment tool widely used clinically to evaluate functional recovery after elbow fractures, arthritis, total joint replacement, or surgery. The scale has a total score of 100 points, with higher scores indicating better elbow function. The scale mainly includes four assessment dimensions: Pain (maximum 45 points), Range of Motion (ROM) (maximum 20 points), Stability (maximum 10 points), and Daily Function (maximum 25 points). |
| Primary | Magnetic Resonance Imaging (MRI) | Baseline and 12 months | Magnetic resonance imaging (MRI) is a medical examination technique that uses a strong magnetic field and radio waves to induce resonance in hydrogen atoms within the body without ionizing radiation, and then reconstructs high-resolution 3D cross-sectional images using a computer. MRI images are used to perform Nelson classification to assess the degree of damage and recovery stability of articular cartilage and subchondral bone in osteochondritis dissecans (OCD). |
| Primary | Elbow ROM (Elbow Range of Motion)(flexion) | Baseline and 1、 3、 6、 12、 18 months. | Elbow ROM refers to the maximum angle and range of motion of the elbow joint under normal conditions in different directions. Flexion: The movement of bending the elbow and bringing the palm closer to the shoulder. The normal angle is approximately 0° to 140°\~150°. |
| Primary | Elbow Range of Motion(Elbow ROM) (extension) | Baseline and 1、 3、 6、 12、 18 months. | Elbow ROM refers to the maximum angle and range of motion of the elbow joint under normal conditions in different directions. Extension: The movement of straightening the elbow. The normal angle is 0° (some people may naturally have a slight hyperextension of 5°\~10°). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884578
GET https://conductscience.org/api/trials/v1/NCT07884578/registered